Balanced Portfolio - SELL (Take profit +13.7%) Telix Phama(TLX)
Date: 17/1/2024
*** GENERAL AVICE ONLY***
Telix Pharmaceuticals (TLX) after a lacklustre earnings report for Telix, we fell there is too much risk in the remainder of our TLX holding until we see further earnings improvement.
We will look to re-enter the trade below $9.50 again closer to next earnings in July
PE: 32
Price to Assets:
Mkt Cap: $4.5B
Telix Pharma (TLX) – Take profit 1% with 0% allocation remaining in the portfolio
Entry: $9.50 | Exit: $10.83| Profit: 13.7%
Disclaimer: The recommendation given is general advice only. It does not take into account your personal objectives, financial situation, or specific needs. This information should not be your sole resource when making such decisions. We strongly recommend you to seek the advice of financial, taxation, and legal professionals before finalising any investment decisions.